Thermo Fisher Scientific Daclizumab Recombinant Human Monoclonal Antibody (Daclizumab)

Applications and Tested Dilution

Product Specifications

Product Specific Information

Specificity: Binds to p55 chain of IL-2 receptor (IL2R) on human T cells, known as Tac antigen. This antigen is expressed on T cells activated by mitogens, soluble antigens, and alloantigens but not on resting T cells, thymocytes, B cells, monocytes, activated B cells, leukemic T cell blasts from patients with acute lymphoblastic leukemia, and long-term T cell lines.

Target Information

Daclizumab is a humanized IgG1 monoclonal antibody that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). It is composed of approximately 90% human and 10% murine antibody sequences.

• Human sequences are derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.
• Murine sequences are derived from the complementarity-determining regions of a murine anti-Tac antibody.

On April 22, 2008, Roche Registration Limited voluntarily withdrew the marketing authorization for Zenapax (daclizumab), used for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation. This withdrawal was for commercial reasons and not due to safety concerns.
Later, Biogen and Abbvie’s Zinbryta (daclizumab) was approved by the FDA in 2016 for the treatment of adult patients with relapsing forms of multiple sclerosis.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.